RBC Capital Bullish on AbbVie: Initiates Coverage with Outperform Rating

RBC Capital’s decision to initiate coverage on AbbVie with an 'Outperform' rating marks a pivotal moment in the market's perception of the biopharmaceutical giant. For years, the 'Humira cliff'—the loss of exclusivity for the world’s formerly top-selling drug—has loomed over AbbVie’s valuation like a permanent shadow. However, RBC’s bullish stance suggests that the worst of the biosimilar erosion is now priced in, and the company’s strategic pivot toward its next-generation immunology assets is yielding results that the broader market has yet to fully appreciate.

The core of the bullish thesis rests on the 'duo' of Skyrizi and Rinvoq. These two drugs were specifically developed to succeed Humira across its various indications, including plaque psoriasis, Crohn’s disease, and rheumatoid arthritis. AbbVie has been remarkably successful in transitioning its patient base and securing favorable formulary placement. Management has previously guided that combined sales for these two products could exceed $27 billion by 2027, a figure that would effectively replace the peak revenue generated by Humira. RBC’s initiation indicates a belief that these targets are not just achievable but potentially conservative, given the drugs' superior clinical profiles compared to legacy biologics.

“

Management has previously guided that combined sales for these two products could exceed $27 billion by 2027, a figure that would effectively replace the peak revenue generated by Humira.

Beyond immunology, AbbVie’s aesthetics franchise, anchored by the Botox brand, provides a unique competitive moat. Unlike traditional therapeutics, which face constant pressure from pharmacy benefit managers (PBMs) and government price negotiations under the Inflation Reduction Act (IRA), the aesthetics business operates largely in a self-pay, consumer-driven market. This provides AbbVie with a durable, high-margin cash flow stream that is relatively insulated from the regulatory headwinds currently battering the rest of the pharmaceutical sector. RBC’s analysis likely weighs this therapeutic diversification as a critical hedge against domestic policy uncertainty.

The regulatory landscape, while often a source of volatility, has recently provided a tailwind. The U.S. Department of Justice recently signaled its support for AbbVie in a legal challenge against a Colorado law aimed at drug discount programs. While specific to one state, the DOJ's involvement suggests a federal interest in protecting the contractual rights of manufacturers within the 340B drug pricing framework. This legal support, combined with the company’s aggressive M&A strategy—including the multi-billion dollar acquisitions of ImmunoGen and Cerevel Therapeutics—demonstrates a management team that is proactively defending its margins while simultaneously rebuilding its oncology and neuroscience pipelines.